The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
The CGM provides real-time glucose readings for 15.5 days. “As a disabled veteran living with Type 2 diabetes, becoming a grandfather has given me a powerful new reason to take charge of my health,” ...
The new AI-powered Smart Food Logging feature supports greater personalized insights into how meals are impacting glucose levels Users can now take a photo of their food in their Stelo or Dexcom G7 ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over ...
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and ...
We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. DexCom, Inc. is one of them. DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) ...
New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Ontario residents eligible for ODB and ...
Health and wellness platform FriskaAi announced an agreement with glucose monitoring specialist Dexcom to integrate data from Dexcom's G7 and G6 continuous glucose monitoring (CGM) systems into the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results